129 related articles for article (PubMed ID: 15698458)
1. Intravenous iron preparations and ascorbic acid: effects on chelatable and bioavailable iron.
Sturm B; Laggner H; Ternes N; Goldenberg H; Scheiber-Mojdehkar B
Kidney Int; 2005 Mar; 67(3):1161-70. PubMed ID: 15698458
[TBL] [Abstract][Full Text] [Related]
2. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo.
Kosch M; Bahner U; Bettger H; Matzkies F; Teschner M; Schaefer RM
Nephrol Dial Transplant; 2001 Jun; 16(6):1239-44. PubMed ID: 11390726
[TBL] [Abstract][Full Text] [Related]
3. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia.
Tarng DC; Wei YH; Huang TP; Kuo BI; Yang WC
Kidney Int; 1999 Jun; 55(6):2477-86. PubMed ID: 10354297
[TBL] [Abstract][Full Text] [Related]
4. Iron sucrose and ferric carboxymaltose: no correlation between physicochemical stability and biological activity.
Praschberger M; Haider K; Cornelius C; Schitegg M; Sturm B; Goldenberg H; Scheiber-Mojdehkar B
Biometals; 2015 Feb; 28(1):35-50. PubMed ID: 25326244
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability and stability of intravenous iron sucrose originator versus generic iron sucrose AZAD.
Praschberger M; Cornelius C; Schitegg M; Goldenberg H; Scheiber-Mojdehkar B; Sturm B
Pharm Dev Technol; 2015 Mar; 20(2):176-82. PubMed ID: 24219061
[TBL] [Abstract][Full Text] [Related]
6. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload.
Tarng DC; Huang TP
Nephrol Dial Transplant; 1998 Nov; 13(11):2867-72. PubMed ID: 9829492
[TBL] [Abstract][Full Text] [Related]
7. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
8. Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation.
Scheiber-Mojdehkar B; Lutzky B; Schaufler R; Sturm B; Goldenberg H
J Am Soc Nephrol; 2004 Jun; 15(6):1648-55. PubMed ID: 15153577
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia.
Deira J; Diego J; Martínez R; Oyarbide A; González A; Díaz H; Grande J
J Nephrol; 2003; 16(5):703-9. PubMed ID: 14733417
[TBL] [Abstract][Full Text] [Related]
10. Effect of intravenous ascorbic acid medication on serum levels of soluble transferrin receptor in hemodialysis patients.
Tarng DC; Hung SC; Huang TP
J Am Soc Nephrol; 2004 Sep; 15(9):2486-93. PubMed ID: 15339999
[TBL] [Abstract][Full Text] [Related]
11. Effect of ascorbic acid administration in hemodialysis patients on in vitro oxidative stress parameters: influence of serum ferritin levels.
Chen WT; Lin YF; Yu FC; Kao WY; Huang WH; Yan HC
Am J Kidney Dis; 2003 Jul; 42(1):158-66. PubMed ID: 12830468
[TBL] [Abstract][Full Text] [Related]
12. Safety of intravenous injection of iron saccharate in haemodialysis patients.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin and iron: the role of ascorbic acid.
Tarng DC; Huang TP; Wei YH
Nephrol Dial Transplant; 2001; 16 Suppl 5():35-9. PubMed ID: 11509682
[TBL] [Abstract][Full Text] [Related]
14. Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis.
Rosenlöf K; Kivivuori SM; Grönhagen-Riska C; Teppo AM; Slimes MA
Clin Nephrol; 1995 Apr; 43(4):249-55. PubMed ID: 7606879
[TBL] [Abstract][Full Text] [Related]
15. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
[TBL] [Abstract][Full Text] [Related]
16. The effect of ascorbic acid and ferric ammonium citrate on iron uptake and storage in lens epithelial cells.
Goralska M; Harned J; Fleisher LN; McGahan MC
Exp Eye Res; 1998 Jun; 66(6):687-97. PubMed ID: 9657901
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review.
Qunibi WY
Arzneimittelforschung; 2010; 60(6a):399-412. PubMed ID: 20648931
[TBL] [Abstract][Full Text] [Related]
18. Effect of intravenous ascorbic acid in hemodialysis patients with anemia and hyperferritinemia.
Shahrbanoo K; Taziki O
Saudi J Kidney Dis Transpl; 2008 Nov; 19(6):933-6. PubMed ID: 18974579
[TBL] [Abstract][Full Text] [Related]
19. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
20. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
